Sugi Predict

Sugi Predict / Compounds / SCHEMBL23328740

SCHEMBL23328740

SCHEMBL23328740

CC(C)(C)OC(=O)N1CC2(C[C@H](N3CCC(c4cc(F)c(F)cc4OCc4ccccc4)CC3)CO2)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 8/20 0.49
▸ CHRM1 P11229 8/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ CHRM2 P08172 3/20 0.38
▸ YAP1 P46937 2/20 0.37
▸ CHRM5 P08912 1/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ GPR119 Q8TDV5 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KLK7 P49862 1/20 0.37
▸ STS P08842 1/20 0.36
▸ TACR1 P25103 1/20 0.36
▸ CCNT1 O60563 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CCNA1 P78396 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23295184 0.92 CHRM4 (0.58) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL23230138 0.92 CHRM4 (0.58) CHRM4CHRM1CHRM2YAP1CHRM5
SCHEMBL23230129 0.92 CHRM4 (0.58) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL23329016 0.90 CHRM4 (0.58) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL29871416 0.88 CHRM4 (0.55) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL23213277 0.88 CHRM4 (0.55) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL23230139 0.88 CHRM4 (0.48) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL23213607 0.88 CHRM4 (0.54) CHRM4CHRM1SMN1; SMN2GAATHRB
SCHEMBL23229959 0.87 CHRM4 (0.51) CHRM4CHRM1CHRM2CHRM5GPR119
SCHEMBL23229960 0.85 CHRM4 (0.50) CHRM4CHRM1CHRM2CHRM5GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 — — US disclosed
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 — — US disclosed
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-12-29 — — US disclosed
US-20210130365-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130365-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885SMN1; SMN2 2919/4885
US-20220411435-A1 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885SMN1; SMN2 2847/4885
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 CHRM4 4/4885CHRM1 2/4885SMN1; SMN2 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.